Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted response-directed therapy in transplant-eligible newly diagnosed multiple myeloma
2019-001258-25Phase 2Unknown
- Sponsor
- University of Leeds
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of isatuximab, lenalidomide, cyclophosphamide, dexamethasone and bortezomib in multiple myeloma (MM) (3 arms), sponsored by University of Leeds. Primary endpoint: Primary outcome measures. Status: unknown.
02
Drugs
isatuximablenalidomidecyclophosphamidedexamethasonebortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2019-001258-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001258-25.